Good
Mostly Aligned
Patient Risk:
Low
Summary
The AI claims are largely general naming/labeling-form statements about dextrose/glucose without providing label-backed specifics from the provided FDA sections. No contraindication, dosing, safety, or indication content was evaluated, but several claims appear unsupported/undetermined because the provided label text does not address generic naming conventions, packaging shorthand, or frequency of usage.
Category Scores
Accurate Statements
Dextrose is a form of glucose.
The provided label text does not explicitly state this relationship; however, the label identifies the active ingredient as dextrose (glucose), supporting that dextrose corresponds to glucose.
Dextrose equals glucose.
The drug description provided includes: "Dextrose Injection, USP (50%) — dextrose (glucose), 50% solution".
Unsupported Statements
Dextrose is also commonly listed as glucose or D-glucose on medical and product labels.
The provided label text does not discuss common listing conventions (e.g., "D-glucose"), nor does it provide evidence about frequency.
Dextrose can be listed on packaging or prescriptions as dextrose injection or dextrose solution.
The provided label text does not describe alternate packaging/prescription naming formats.
Dextrose can be listed on packaging or prescriptions as dextrose (glucose).
The provided label describes the specific product naming, but does not support broader claims about how packaging/prescriptions are commonly written.
Dextrose can be listed on packaging or prescriptions as glucose (dextrose).
The provided label does not support this specific re-ordering/formatting claim.
There is no more than one generic name for dextrose.
The provided label does not address the number of generic names or naming/regulatory conventions.
Different label forms usually reflect concentration, such as D10, D25, or D50.
The provided label does not discuss naming schemes like D10/D25, nor does it state that forms usually reflect concentration.
Different label forms usually reflect the formulation, such as injection versus oral solution.
The provided label does not describe how label forms usually reflect formulation (e.g., injection vs oral solution).
Dextrose is the more common term in many IV and nutrition contexts.
The provided label does not support claims about relative term frequency in IV/nutrition contexts.
Glucose is frequently used in clinical chemistry and broader drug labeling.
The provided label does not support claims about how often glucose is used in clinical chemistry or broader drug labeling.
Contradictions
Important Omissions
No omission is identified because the AI claims do not request dosage/administration, contraindications, boxed warnings, monitoring, interactions, or adverse-reaction specifics, which are present in the provided label text.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The AI claims are about naming/labeling conventions and do not include dosing, contraindications, or safety instructions. One statement is supported by the provided product identification (dextrose (glucose)); other statements about common naming practices are unsupported but also not directly prescribing use.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Aligned
Primary Issue
Several claims about how dextrose/glucose are commonly listed on packaging/prescriptions and about naming conventions (e.g., D10/D25/D50, term frequency) are not supported by the provided FDA label excerpts.
Suggested Improvement
Limit statements to what is directly supported by the provided label text (e.g., the product naming identifies dextrose as dextrose (glucose)) and avoid claims about frequency or generic naming conventions unless supported by the label.